Drugs / IVIEW-1201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06463678 | Aug 2026 → Dec 2027 expected | fungal keratitis | IVIEW Therapeutics Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-11-17 | IVIEW Therapeutics Inc. | Regulatory IVIEW Therapeutics’ Investigational Ophthalmic Drug IVIEW-1201D Has Its Phase III IND Cleared by the FDA for Adenoviral Conjunctivitis iviewtherapeutics.com ↗
IVIEW Therapeutics (“IVIEW”) today announced that its investigational ophthalmic drug, IVIEW-1201D, has received U.S. Food and Drug Administration (FDA) Phase III IND clearance for the treatment of adenoviral conjunctivitis. |
| 2025-04-02 | IVIEW Therapeutics Inc. | Regulatory IVIEW Therapeutics Inc. Announces FDA Grants Orphan Drug Designation to IVW-1201 for the Treatment of Fungal Keratitis iviewtherapeutics.com ↗
April 2, 2025 – Cranbury, New Jersey – IVIEW Therapeutics Inc., a clinical-stage biotechnology company focused on innovative ophthalmic treatments, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to IVIEW-1201 (1.0% povidone-iodine ophthalmic gel sterile solution) for the treatment of Fungal Keratitis (FK). |
| 2024-02-28 | IVIEW Therapeutics Inc. | Results IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024 iviewtherapeutics.com ↗
The prespecified primary endpoint (clinical cure rate at Day 8) of non-inferiority to Ofloxacin achieved. |
| 2019-06-06 | IVIEW Therapeutics Inc. | Regulatory IVW-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA iviewtherapeutics.com ↗
today announced that its Phase II clinical trial IND application of iVIEW-1201 was been accepted by US FDA. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVIEW-1201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06463678 ↗ |
| Route | Other | “administer 1 drop into the conjunctival sac” NCT06463678 ↗ |